James Boylan Purchases ZBIO Shares
James Boylan acquired 18,500 shares of ZBIO on June 15, 2026.
Key Points
- James Boylan bought 18,500 shares of ZBIO on June 15, 2026, with the stock priced at $18.58.
- Shares of ZBIO are trading near $18.58, with insider buying activity noted on the same date.
- Analysts like Morgan Stanley and Citigroup have maintained ratings on ZBIO, with targets ranging from $19 to $55.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
James Boylan made a move on June 15, 2026, by purchasing 18,500 shares of ZBIO. This insider transaction comes as the stock was trading at $18.58. Boylan's acquisition is part of broader insider activity within the company.
Insider Buying and Selling at Zenas BioPharma, Inc.
In addition to James Boylan, several other insiders bought shares on June 15, 2026. Patricia Allen, Jason Raleigh Nunn, and Joseph Farmer, the President and Chief Operating Officer, each purchased 18,500 shares. Lisa Von Moltke, Head of Research and Development and Chief Medical Officer, acquired 150,000 shares, and Jennifer Fox, the Chief Business Officer and Chief Financial Officer, bought 125,000 shares. These transactions were not made under any pre-planned 10b5-1 trading plans.
Other Institutional Activity in ZBIO
FMR LLC increased its holdings by 1,377,745 shares, ending with 9,082,000 shares valued at approximately $177.6 million. NEA Management Company, LLC also grew its position, adding 500,000 shares for a total of 4,023,219 shares worth around $78.7 million. Federated Hermes, Inc. added 411,453 shares, bringing its total to 3,127,031 shares valued at $61.1 million. Meanwhile, Polar Capital Holdings PLC made a significant increase of 1,490,835 shares, resulting in 2,548,444 shares worth about $49.8 million.
Zenas BioPharma, Inc. Stock Down 40.6%
Shares of ZBIO are currently trading near $18.58. While detailed fundamentals are not provided, the stock has seen active trading and interest from both insiders and institutional investors.
Analysts Set New Price Targets
On May 14, 2026, Morgan Stanley maintained a 'hold' rating on ZBIO, setting a price target of $22. Previously, Citigroup and Guggenheim had maintained 'buy' ratings with targets of $41 and $55, respectively, on March 17, 2026. HC Wainwright & Co. reiterated a 'buy' rating with a $44 target on February 10, 2026.
Bottom Line
James Boylan's purchase of 18,500 shares of ZBIO highlights insider confidence in the company's prospects. The stock's trading activity and analyst ratings offer additional context for investors. As always, it's important to remember that insider transactions are reported after they occur and may not reflect the current state of holdings.
Get Zenas BioPharma, Inc. alerts
New 13F filings, insider trades, and analyst moves on $ZBIO, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.